1-20 of 36
Chris Fegan
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

An Unsupervised Machine Learning Method Stratifies Chronic Lymphocytic Leukemia Patients into Novel Categories with Different Risk of Early Treatment

Federico Pozzo, Francesca Cuturello, Edith Villegas Garcia, Francesca Rossi, Massimo Degan, Paola Nanni, Ilaria Cattarossi, Eva Zaina, Paola Varaschin, Alessandra Braida, Michele Berton, Laura Zannier, Filippo Vit, Erika Tissino, Tamara Bittolo, Roberta Laureana, Giovanni Francesco D'Arena, Luca Laurenti, Agostino Tafuri, Jacopo Olivieri, Francesco Zaja, Annalisa Chiarenza, Francesco Di Raimondo, Maria Ilaria Del Principe, Riccardo Bomben, Antonella Zucchetto, Alessio Ansuini, Chris Fegan, Chris Pepper, Andrea Pepper, Kari G. Rabe, Sameer A. Parikh, Neil E. Kay, Alberto Cazzaniga, Valter Gattei
Journal: Blood
Blood (2023) 142 (Supplement 1): 1892.
https://doi.org/10.1182/blood-2023-177884
Published: 2023
Journal Articles

Phenotype and immune function of lymph node and peripheral blood CLL cells are linked to transendothelial migration

Marta Pasikowska, Elisabeth Walsby, Benedetta Apollonio, Kirsty Cuthill, Elizabeth Phillips, Eve Coulter, Maria Serena Longhi, Yun Ma, Deborah Yallop, Linda D. Barber, Piers Patten, Chris Fegan, Alan G. Ramsay, Chris Pepper, Stephen Devereux, Andrea G. S. Buggins
Journal: Blood
Blood (2016) 128 (4): 563–573.
https://doi.org/10.1182/blood-2016-01-683128
Published: 2016
Includes: Supplemental data
Journal Articles

Development and characterization of a physiologically relevant model of lymphocyte migration in chronic lymphocytic leukemia

Elisabeth Walsby, Andrea Buggins, Stephen Devereux, Ceri Jones, Guy Pratt, Paul Brennan, Chris Fegan, Chris Pepper
Journal: Blood
Blood (2014) 123 (23): 3607–3617.
https://doi.org/10.1182/blood-2013-12-544569
Published: 2014
Includes: Supplemental data
Journal Articles

Lymph Node Derived CLL Cells Have a More Activated Phenotype and Better Antigen Presentation Capabilities Compared To Those From The Peripheral Blood

Andrea GS Buggins, Ph.D., Marta Pasikowska, Ph.D., Elisabeth J Walsby, Ph.D., Kirsty M Cuthill, MBBS, MRCP, FRCPath, Maria Longhi, Ph.D., Emma Hamilton, MBiochem, Linda Barber, Ph.D., Chris Fegan, MBBS, Chris Pepper, Ph.D., Stephen Devereux, FRCP, FRCPath, PhD
Journal: Blood
Blood (2013) 122 (21): 4119.
https://doi.org/10.1182/blood.V122.21.4119.4119
Published: 2013
Journal Articles

A Phase I Study Of The Oral Btk Inhibitor ONO-4059 In Patients With Relapsed/Refractory B-Cell Lymphoma

Simon Rule, MD, Nimish Shah, MD, Gilles Andre Salles, MD, PhD, Lionel Karlin, MD, Franck Morschhauser, MD, PhD, Louis Terriou, MD, Martin JS Dyer, MA, DPhil, FRCP, FRCPath, Claire Hutchinson, BMedSci, MRCP, FRCPath, Chris Fegan, MBBS, Guillaume Cartron, MD, PhD, Tomasz Knurowski, MD, James G Wright, PhD, Andrew J Saunders, MD, Hideyuki Honda, Bsc, Andrew Mazur, Toshio Yoshizawa, PhD, Kazuhito Kawabata, PhD, Joseph TP Birkett, PhD
Journal: Blood
Blood (2013) 122 (21): 4397.
https://doi.org/10.1182/blood.V122.21.4397.4397
Published: 2013
Journal Articles

Longitudinal Analysis Reveals Telomere Length Maintenance In CLL B-Cells But Marked Erosion In CLL Patient T-Cells

Ceri Jones, Thet Lin, Guy Pratt, Chris Fegan, Duncan Baird, Chris Pepper
Journal: Blood
Blood (2013) 122 (21): 1617.
https://doi.org/10.1182/blood.V122.21.1617.1617
Published: 2013
Journal Articles

Characterization Of a Novel In Vitro Circulation System Designed To Model The Migration Of Primary CLL Cells Across The Vascular Endothelium

Elisabeth J Walsby, Andrea GS Buggins, Ph.D., Stephen Devereux, FRCP, FRCPath, PhD, Paul Brennan, Chris Fegan, Chris Pepper
Journal: Blood
Blood (2013) 122 (21): 667.
https://doi.org/10.1182/blood.V122.21.667.667
Published: 2013
Journal Articles

CD49d Is The Strongest Flow Cytometry-Based Predictor Of Overall Survival In Chronic Lymphocytic Leukemia

Pietro Bulian, MD, Tait D Shanafelt, MD, Chris Fegan, MBBS, Antonella Zucchetto, Lilla Cro, PhD, Holger Nuckel, MD, Luca Baldini, Antonina Kurtova, MS, Alessandra Ferrajoli, MD, Jan A. Burger, MD, PhD, Gianluca Gaidano, Giovanni Del Poeta, MD, Chris Pepper, Ph.D., Davide Rossi, Valter Gattei
Journal: Blood
Blood (2013) 122 (21): 672.
https://doi.org/10.1182/blood.V122.21.672.672
Published: 2013
Journal Articles

A Phase I Study Of The Oral Btk Inhibitor ONO-4059 In Patients With Relapsed/Refractory and High Risk Chronic Lymphocytic Leukaemia (CLL)

Gilles Andre Salles, MD, PhD, Lionel Karlin, MD, Simon Rule, MD, Nimish Shah, MD, Franck Morschhauser, MD, PhD, Louis Terriou, MD, Martin JS Dyer, MA, DPhil, FRCP, FRCPath, Claire Hutchinson, BMedSci, MRCP, FRCPath, Chris Fegan, MBBS, Guillaume Cartron, MD, PhD, Tomasz Knurowski, MD, Andrew J Saunders, MD, James G Wright, PhD, Hideyuki Honda, Bsc, Andrew Mazur, Toshio Yoshizawa, PhD, Kazuhito Kawabata, PhD, Joseph TP Birkett, PhD
Journal: Blood
Blood (2013) 122 (21): 676.
https://doi.org/10.1182/blood.V122.21.676.676
Published: 2013
Journal Articles

Prognostic Relevance of CD49d Expression On B Leukemic Cells in Chronic Lymphocytic Leukemia. Meta-Analysis of Published and unpublished Individual Data From 3146 Patients

Pietro Bulian, MD, Tait D. Shanafelt, MD, Chris Pepper, Chris Fegan, Giovanni Del Poeta, Gianluca Gaidano, MD, PhD, Davide Rossi, MD, PhD, Luca Baldini, Lilla Cro, PhD, Holger Nuckel, MD, Jan A. Burger, MD, PhD, Valter Gattei, MD
Journal: Blood
Blood (2012) 120 (21): 3871.
https://doi.org/10.1182/blood.V120.21.3871.3871
Published: 2012
Journal Articles

CLL: a supplementary question?

Chris Pepper, Chris Fegan
Journal: Blood
Blood (2011) 117 (5): 1439–1440.
https://doi.org/10.1182/blood-2010-11-318451
Published: 2011
Journal Articles

NCRN CLL207 Study of Alemtuzumab Consolidation In CLL: Final Response Assessment and Early Follow-up (on Behalf of the NCRI CLL Trials Sub-Group)

Abraham M Varghese, Dena Cohen, Christopher F.E. Pocock, MD, PhD, Andy Rawstron, PhD, Walter M Gregory, Alex Smith, Emma Skinner, BSc, Anne Critchley, MB, BS, Donald Milligan, MD, FRCP, FRCPath, Claire E. Dearden, MD, Helen McCarthy, Chris Fegan, George A Follows, Peter Hillmen, MBChB, FRCP, FRCPath, PhD
Journal: Blood
Blood (2010) 116 (21): 60.
https://doi.org/10.1182/blood.V116.21.60.60
Published: 2010
Journal Articles

Polyclonal Serum FLC Levels: a Simple Risk Stratification Model for Identifying Aggressive Stage A CLL.

Guy Pratt, Alison Levoguer, Jeffrey Faint, Chris Fegan, Chris Pepper, David Graham Oscier, MD, Anne Gardiner, Stephen Harding, PhD
Journal: Blood
Blood (2010) 116 (21): 4608.
https://doi.org/10.1182/blood.V116.21.4608.4608
Published: 2010
Journal Articles

The number of cytomegalovirus-specific CD4 + T cells is markedly expanded in patients with B-cell chronic lymphocytic leukemia and determines the total CD4 + T-cell repertoire

Batoul Pourgheysari, Rachel Bruton, Helen Parry, Lucinda Billingham, Chris Fegan, Jim Murray, Paul Moss
Journal: Blood
Blood (2010) 116 (16): 2968–2974.
https://doi.org/10.1182/blood-2009-12-257147
Published: 2010
Journal Articles

Telomere dysfunction and fusion during the progression of chronic lymphocytic leukemia: evidence for a telomere crisis

Thet Thet Lin, Boitelo T. Letsolo, Rhiannon E. Jones, Jan Rowson, Guy Pratt, Saman Hewamana, Chris Fegan, Chris Pepper, Duncan M. Baird
Journal: Blood
Blood (2010) 116 (11): 1899–1907.
https://doi.org/10.1182/blood-2010-02-272104
Published: 2010
Includes: Supplemental data
Journal Articles

Two Distinct Co-Culture Systems, Designed to Mimic the Tumor Microenvironment, Induce Remarkably Similar Phenotypic Changes in Primary CLL Cells.

Andrea Gail Sherman Buggins, Ph.D., Laurence Pearce, B.Sc, Piers EM Patten, BSc, MRCP, MRCPath, Liam Morgan, Paul Brennan, Chris Fegan, Stephen Devereux, FRCP, FRCPath, Chris J Pepper
Journal: Blood
Blood (2009) 114 (22): 2362.
https://doi.org/10.1182/blood.V114.22.2362.2362
Published: 2009
Journal Articles

Serum FLC Levels at Presentation Have Independent Prognostic Significance in CLL and Levels Above 50mg/L Identify Patients with Progressive Disease.

Guy Pratt, Stephen Harding, PhD, Chris Fegan, Chris J Pepper, David Oscier, Anne Gardiner, Roger Holder, Arthur Bradwell, FRCP, FRCPath, Graham Mead, PhD
Journal: Blood
Blood (2009) 114 (22): 2355.
https://doi.org/10.1182/blood.V114.22.2355.2355
Published: 2009
Journal Articles

The DNA Crosslinking Agent SJG-136 (SG2000, BN2629) Is Highly Potent in Acute Myeloid Leukaemia and Is Synergistic with Cytarabine

Elisabeth J Walsby, Alan Burnett, Steven Knapper, Chris Fegan, Chris Pepper
Journal: Blood
Blood (2008) 112 (11): 4013.
https://doi.org/10.1182/blood.V112.11.4013.4013
Published: 2008
Journal Articles

Rel a Is a Novel Prognostic Marker in CLL That Is Independent of V H Gene Mutation Status, CD38 Expression and ZAP-70 Expression

Saman Hewamana, Thet Thet Lin, Clare Rowntree, Kamaraj Karunanithi, Alan Burnett, Paul Brennan, Chris Fegan, Chris Pepper
Journal: Blood
Blood (2008) 112 (11): 4153.
https://doi.org/10.1182/blood.V112.11.4153.4153
Published: 2008
Journal Articles

A Common Genetic Variant in the 3′UTR of IRF4/MUM1 Associates with Risk of Disease and Poor Prognosis in Chronic Lymphocytic Leukaemia.

James M Allan, Nicola Sunter, Andrew Hall, Tryfonia Mainou-Fowler, Graham Jackson, Geoffrey Summerfield, Robert John Harris, PhD, Andrew Pettitt, Richard Houlston, James Bailey, Chris Pepper, Chris Fegan, Guy Pratt, David J Allsup, MRCP., MRCPath., PhD.
Journal: Blood
Blood (2008) 112 (11): 1060.
https://doi.org/10.1182/blood.V112.11.1060.1060
Published: 2008